Patients with cardioembolic ischemic stroke are commonly prescribed direct oral anticoagulants (DOACs), such as dabigatran (a direct thrombin inhibitor) and factor Xa inhibitors (e.g., apixaban and rivaroxaban), or warfarin to reduce the risk of recurrent stroke. A major concern in anticoagulant therapy is the risk of intracerebral hemorrhage, which is associated with a high mortality rate. Cerebral microbleeds (MBs), small asymptomatic brain hemorrhages detectable by susceptibility-weighted imaging (SWI) on magnetic resonance imaging (MRI), are associated with increased hemorrhagic stroke risk. This study evaluated the incidence of new MBs during 1 year of anticoagulation therapy in patients after cardioembolic stroke. Patients indicated for anticoagulant therapy after cardioembolic stroke and monitored in the cerebrovascular outpatient clinic of our department underwent brain MRI at baseline and after 1 year of therapy. The occurrence of new MBs was assessed using SWI sequences. MBs were categorized based on location into 3 groups: deep (dMBs), lobar (lMBs), and infratentorial (iMBs). A total of 79 patients were included, 53 of whom were male (67.1%), with a median age of 71 years (IQR: 64-76). The majority of patients (n = 50, 63.3%) were treated with apixaban, 16 patients (20.3%) with dabigatran, and 13 patients (16.5%) with warfarin. Baseline MRI revealed MBs in 17 patients (21.5%), including dMBs in 2, lMBs in 16, and iMBs in 2 patients. Follow-up MRI showed new MBs in 8 patients (10.1%), with new dMBs in 1, lMBs in 5, and iMBs in 4 patients. No statistically significant differences were observed in MBs the incidence of new MBs between anticoagulant groups (P = .912). Over 1 year of anticoagulant therapy, new MBs were detected in 10.1% of patients, predominantly in lobar and infratentorial regions. No differences in the incidence of new MBs were identified between the different anticoagulant groups.

Department of Neurology 2nd Faculty of Medicine Charles University and Motol University Hospital Motol Prague Czech Republic

Department of Neurology Jihlava Hospital Czech Republic

Department of Neurology Military University Hospital Prague Czech Republic

Department of Pathophysiology 2nd Faculty of Medicine Charles University and Motol University Hospital Motol Prague Czech Republic

Department of Radiology 2nd Faculty of Medicine Charles University and Motol University Hospital Motol Prague Czech Republic

Zobrazit více v PubMed

Dawson J, Béjot Y, Christensen LM, et al. . European Stroke Organisation (ESO) guideline on pharmacological interventions for long-term secondary prevention after ischaemic stroke or transient ischaemic attack. Eur Stroke J. 2022;7:I–II. PubMed PMC

Broderick JP, Brott TG, Duldner JE, Tomsick T, Huster G. Volume of intracerebral hemorrhage. a powerful and easy-to-use predictor of 30-day mortality. Stroke. 1993;24:987–93. PubMed

Wilson D, Ambler G, Shakeshaft C, et al. ; CROMIS-2 collaborators. Cerebral microbleeds and intracranial haemorrhage risk in patients anticoagulated for atrial fibrillation after acute ischaemic stroke or transient ischaemic attack (CROMIS-2): a multicentre observational cohort study. Lancet Neurol. 2018;17:539–47. PubMed PMC

Bokura H, Saika R, Yamaguchi T, et al. . Microbleeds are associated with subsequent hemorrhagic and ischemic stroke in healthy elderly individuals. Stroke. 2011;42:1867–71. PubMed

Van Etten ES, Auriel E, Haley KE, et al. . Incidence of symptomatic hemorrhage in patients with lobar microbleeds. Stroke. 2014;45:2280–5. PubMed PMC

Charidimou A, Karayiannis C, Song TJ, et al. ; International META-MICROBLEEDS Initiative. Brain microbleeds, anticoagulation, and hemorrhage risk: meta-analysis in stroke patients with AF. Neurology. 2017;89:2317–26. PubMed

Wadi LC, Grigoryan MM, Kim RC, et al. . Mechanisms of cerebral microbleeds. J Neuropathol Exp Neurol. 2021;79:1093–9. PubMed PMC

Poels MMF, Vernooij MW, Ikram MA, et al. . Prevalence and risk factors of cerebral microbleeds: an update of the rotterdam scan study. Stroke. 2010;41(10 Suppl):S103–6. PubMed

Choi KH, Kim JH, Lee C, et al. . Microbleeds and outcome in patients with acute ischemic stroke and atrial fibrillation taking anticoagulants. Stroke. 2020;51:3514–22. PubMed

Wilson D, Ambler G, Lee KJ, et al. ; Microbleeds International Collaborative Network. Cerebral microbleeds and stroke risk after ischaemic stroke or transient ischaemic attack: a pooled analysis of individual patient data from cohort studies. Lancet Neurol. 2019;18:653–65. PubMed PMC

Gregoire SM, Brown MM, Kallis C, Jäger HR, Yousry TA, Werring DJ. MRI detection of new microbleeds in patients with ischemic stroke: five-year cohort follow-up study. Stroke. 2010;41:184–6. PubMed

Zhuang L, Zhai L, Qiao S, et al. . New cerebral microbleeds in AF patients on non-vitamin K oral anticoagulants or warfarin: one-year follow-up. Medicine (Baltimore). 2022;101:e25836. PubMed PMC

Saito T, Kawamura Y, Sato N, et al. . Non-vitamin K antagonist oral anticoagulants do not increase cerebral microbleeds. J Stroke Cerebrovasc Dis. 2015;24:1373–7. PubMed

O’Donnell MJ, Eikelboom JW, Yusuf S, et al. . Effect of apixaban on brain infarction and microbleeds: AVERROES-MRI assessment study. Am Heart J. 2016;178:145–50. PubMed

Cho MS, Kim M, Lee SA, et al. . Comparison of dabigatran versus warfarin treatment for prevention of new cerebral lesions in valvular atrial fibrillation. Am J Cardiol. 2022;175:58–64. PubMed

Tomek A, Růžičková T, Kaplan V, et al. . Pharmacogenetic algorithm for predicting daily dose of warfarin in Caucasian patients of Czech origin. Drug Metab Pers Ther. 2021;36:123–8. PubMed

Tomek A, Maťoška V, Kolářová T, et al. . The bleeding risk during warfarin therapy is associated with the number of variant alleles of CYP2C9 and VKORC1 genes. Cardiology. 2013;125:182–91. PubMed

Adams HP, Bendixen BH, Kappelle LJ, et al. . Classification of subtype of acute ischemic stroke definitions for use in a multicenter clinical trial. Stroke. 1993;24:35–41. PubMed

Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in Alzheimer’s dementia and normal aging. AJR Am J Roentgenol. 1987;149:351–6. PubMed

Cordonnier C, Potter GM, Jackson CA, et al. . Improving interrater agreement about brain microbleeds: development of the Brain Observer MicroBleed Scale (BOMBS). Stroke. 2009;40:94–9. PubMed

Greenberg SM, Vernooij MW, Cordonnier C, et al. ; Microbleed Study Group. Cerebral microbleeds: a guide to detection and interpretation. Lancet Neurol. 2009;8:165–74. PubMed PMC

Wardlaw JM, Smith EE, Biessels GJ, et al. ; STandards for ReportIng Vascular changes on nEuroimaging (STRIVE v1). Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013;12:822–38. PubMed PMC

Umemura T, Mashita S, Kawamura T. Oral anticoagulant use and the development of new cerebral microbleeds in cardioembolic stroke patients with atrial fibrillation. PLoS One. 2020;15:e0238456. PubMed PMC

Orken DN, Uysal E, Timer E, Kuloglu-Pazarci N, Mumcu S, Forta H. New cerebral microbleeds in ischemic stroke patients on warfarin treatment: two-year follow-up. Clin Neurol Neurosurg. 2013;115:1682–5. PubMed

Yokoyama M, Mizuma A, Terao T, et al. ; CMB-NOW Study Investigators. Effectiveness of nonvitamin K antagonist oral anticoagulants and warfarin for preventing further cerebral microbleeds in acute ischemic stroke patients with nonvalvular atrial fibrillation and at least one microbleed: CMB-NOW multisite pilot trial. J Stroke Cerebrovasc Dis. 2019;28:1918–25. PubMed

Koennecke HC. Cerebral microbleeds on MRI: prevalence, associations, and potential clinical implications. Neurology. 2006;66:165–71. PubMed

Mehndiratta MM, Khan M, Mehndiratta P, Wasay M. Stroke in Asia: geographical variations and temporal trends. J Neurol Neurosurg Psychiatry. 2014;85:1308–12. PubMed

Cheng Y, Wang Y, Song Q, Qiu K, Liu M. Use of anticoagulant therapy and cerebral microbleeds: a systematic review and meta-analysis. J Neurol. 2021;268:1666–79. PubMed